Panacea Index Logo

Command Palette

Search for a command to run...

The effect of blister packaging Iron and Folate on adherence to medication and hemoglobin levels among pregnant women at National Referral Hospital antenatal clinics in a low to middle income country: a Randomised Controlled Trial (The IFAd Trial).

BMC pregnancy and childbirth
January 1, 1970
Josaphat Byamugisha et al. (11 authors)
Journal ArticleRandomized Controlled TrialHuman StudyClinical
Study Details

Study Goal

The researchers aimed to determine whether blister-packaged Iron-Folic acid (IFA) pills improved adherence and hemoglobin levels compared to loose-packaged pills among pregnant women in Uganda.

Results Summary

The study found no significant difference in IFA adherence between blister and loose packaging groups, but blister packaging led to a higher increase in hemoglobin levels over 8 weeks. Hemoglobin levels were slightly higher in the blister group at 4 weeks, but similar at 8 weeks, with a greater overall change in the blister group.

Population

Pregnant women (≤28 weeks gestation) at two National Referral Hospitals in Kampala, Uganda.

Effective Dosage

30 IFA pills (one pill per day).

Duration

8 weeks.

Interactions

None mentioned.

Extracted Claims (6)
InterventionDirectionEndpointPopulationDosageImpactClaim #
blister packaged Iron-Folic acid (IFA) pills
increase
hemoglobin level
pregnant women at two National Referral Hospitals in Kampala, Uganda
11.9 + 1.1 g/dl vs 11.8 + 1.3 g/dl
had a higher mean hemoglobin level
#1
blister packaged Iron-Folic acid (IFA) pills
increase
hemoglobin level
pregnant women at two National Referral Hospitals in Kampala, Uganda
0.6 ± 1.0 vs 0.2 ± 1.1; difference: 0.4 g/dL (95% CI: 0.24-0.51 g/dL)
had a higher change in hemoglobin level
#2
blister packaged Iron-Folic acid (IFA) pills
no change
IFA adherence
pregnant women at two National Referral Hospitals in Kampala, Uganda
-
showed no effect on IFA adherence
#3
blister packaged Iron-Folic acid (IFA) pills
no change
adherence to IFA intake
pregnant women at two National Referral Hospitals in Kampala, Uganda
40.6% vs 39.0% at 4th week
was similar in adherence
#4
blister packaged Iron-Folic acid (IFA) pills
no change
adherence to IFA intake
pregnant women at two National Referral Hospitals in Kampala, Uganda
51.9% vs 46.8% at 8th week
was similar in adherence
#5
blister packaged Iron-Folic acid (IFA) pills
no change
hemoglobin level
pregnant women at two National Referral Hospitals in Kampala, Uganda
12.1 + 1.2 vs 12.0 + 1.3 at week 8
had similar mean hemoglobin level
#6
Abstract

INTRODUCTION: Anemia in pregnancy is an important global public health problem. It is estimated that 38% of pregnant women worldwide are anemic. In Africa, literature from observational studies show 20% of maternal deaths are attributed to anemia. In Uganda, 50% of pregnant women have iron deficiency anaemia. The proportion of pregnant women receiving Iron-Folic acid (IFA) supplementation has improved. However, the number of IFA pills consumed is still low. We carried out a randomized controlled trial to determine the effect of dispensing blister and loose packaged IFA pills on adherence measured by count on next return visit and hemoglobin levels among pregnant women at two National Referral Hospitals in Kampala, Uganda. METHODS: This trial was conducted between April and October 2016. Nine hundred fifty pregnant women at ≤28 weeks were randomized to either the blister (intervention arm) or loose (control arm) packaged IFA. The participants completed the baseline measurements and received 30 pills of IFA at enrolment to swallow one pill per day. We assessed adherence by pill count and measured hemoglobin at four and 8 weeks. The results were presented using both intention-to-treat and per-protocol analysis. RESULTS: There were 474 participants in the control and 478 in the intervention arms. Adherence to IFA intake was similar in the two groups at 4th week (40.6 and 39.0%, p = 0.624) and 8th week (51.9 and 46.8%, p = 0.119). The mean hemoglobin level at 4 weeks was higher in the blister than in the loose packaging arms (11.9 + 1.1 g/dl and 11.8 + 1.3 g/dl, respectively; p = 0.02), however, similar at week 8 (12.1 + 1.2 and 12.0 + 1.3, respectively; p = 0.23). However, over the 8-week period blister packaging arm had a higher change in hemoglobin level compared to loose package (blister package 0.6 ± 1.0; loose packaging 0.2 ± 1.1; difference: 0.4 g/dL (95% CI: 0.24-0.51 g/dL); p = 0.001. There were no serious adverse events. CONCLUSIONS: Our results showed no effect of blister packaging on IFA adherence among pregnant women. However, our findings showed that blister packaged group had a higher hemoglobin increase compared to loose iron group. TRIAL REGISTRATION: No. PACTR201707002436264 (20 /07/ 2017).

Medical Subject Headings (MeSH)
AdultAnemia, Iron-DeficiencyDietary SupplementsDrug PackagingFemaleFolic AcidHumansIron, DietaryMedication AdherencePregnancyPregnancy Complications, HematologicPrenatal CareTabletsUganda
Study Links
Quality Scores
Safety95
Efficacy75/10
Quality85/10
Citation Metrics
Total Citations3
Citations/Year1.0
Relative Citation Ratio0.60
NIH Percentile32.6%
Research Impact Scores
APT Score0.25
Weight Score1.58
Normalized Score0.85
Related Supplements